NanoBio, GSK Leave Rx Drug Path To Take "Remarkable" Cold Sore Med OTC
This article was originally published in The Rose Sheet
Executive Summary
Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow, aiming straight for the OTC market with the help of GlaxoSmithKline
You may also be interested in...
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion with the acquisition of Stiefel Laboratories, a move that provides GSK a foothold in the U.S. market for nonprescription skin-care products
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program